- Aduro Biotech (NASDAQ:ADRO) announces that licensee Janssen Biotech (JNJ) has initiated a Phase 1b clinical trial assessing ADU-214, combined with Bristol-Myers Squibb's (BMY) Opdivo (nivolumab), in patients with advanced/metastatic non-small cell lung cancer, specifically, mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung.
- The primary endpoint of the 170-subject study is objective response rate (ORR) at every eight-week time point during year 1 and every 12 weeks thereafter. According to ClinicalTrials.gov, the estimated primary completion date is October 2020.
- ADU-214 is based on Aduro's LADD technology platform. LADD (live-attenuated double-deleted) Listeria monocytogenes are strains of bacteria that are engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T-cell-mediated immunity.
- Shares are up 1% after hours.
- Previously: Aduro bags $22.4M in LADD-related milestones from Janssen Biotech (Feb. 1, 2016)